Table 2.
Evaluation of mutagenicity and antimutagenicity against doxorubicin for genistein or daidzein on HTC cells, determined by micronucleus assay
| Treatments | Mean ± SD | DR % | NDI |
|---|---|---|---|
| Control | 8.33 ± 0.57b | 1.86 | |
| DXR | 65.66 ± 0.57a*** | 1.84 | |
| Genistein 10 μM | 8.33 ± 0.57a | 1.87 | |
| Daidzein 10 μM | 9.33 ± 0.57a | 1.9 | |
| Genistein 0.1 μM + DXR | 61.66 ± 3.21b | 6.43 | 1.89 |
| Genistein 1 μM + DXR | 56.00 ± 10.44b | 16.37 | 1.85 |
| Genistein 10 μM + DXR | 43.33 ± 2.88b*** | 38.59 | 1.83 |
| Daidzein 0.1 μM + DXR | 62.00 ± 2.64b | −0.01 | 1.88 |
| Daidzein 1 μM + DXR | 59.66 ± 4.72b | −1.76 | 1.85 |
| Daidzein 10 μM + DXR | 65.00 ± 5.00b | 0.58 | 1.85 |
DR % percent reduction, NDI nuclear division index, DXR doxorubicin (0.2 μM)
*** Statistically significant difference
aCompared statiscally to the control
bCompared statiscally to DXR. Values are expressed as the mean of micronucleus in 1,000 analysed cells ± SD